Ranbaxy shares fall on FDA concerns
Reuters Market Eye - Ranbaxy Laboratories(RANB.NS) shares fall 2 percent, adding to Monday's 5.4 percent slump after the U.S. Food and Drug Administration raised concerns about manufacturing practices at one of its factories.
Macquarie and Jefferies downgrade Ranbaxy, saying the FDA uncertainty could put pressure on valuations in the near-term till further clarity emerges.
Macquarie downgrades the stock to "neutral" from "outperform" and cuts the price target to 450 rupees from 500 rupees, while Jefferies cuts Ranbaxy to "underperform" from "hold" with a price target of 350 rupees.
Ranbaxy said on Monday the FDA has filed "certain observations" about its Toansa pharmaceutical ingredients plant in Punjab.
"The issue also increases the risk of delay in resolution of import alerts and launch of products," Jefferies said in a note to clients.
(Reporting by Indulal PM)
- Tweet this
- Share this
- Digg this
- Malaysian plane still missing; questions over false IDs
- UPDATE 6-Libya threatens to bomb N.Korean tanker if it ships oil from rebel port
- Australia's Wesfarmers plans A$1.12 billion insurance spinoff - report
- Michigan woman dead for six years found only after money runs out
- WRAPUP 3-Malaysia Airlines plane missing at sea off Vietnam, presumed crashed
PLANE GOES MISSING
A Malaysia Airlines flight carrying 227 passengers and 12 crew was presumed to have crashed off the Vietnamese coast on Saturday, and European officials said two people on board were using false identities. Full Article